It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 0 FA rating(s) are green whileCRON’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 5 TA indicator(s) are bullish while CRON’s TA Score has 4 bullish TA indicator(s).
ACB (@Pharmaceuticals: Other) experienced а -0.93% price change this week, while CRON (@Pharmaceuticals: Other) price change was +1.04% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.34%. For the same industry, the average monthly price growth was -0.19%, and the average quarterly price growth was -10.14%.
ACB is expected to report earnings on Feb 06, 2025.
CRON is expected to report earnings on Mar 04, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
ACB | CRON | ACB / CRON | |
Capitalization | 239M | 1.01B | 24% |
EBITDA | -1.64B | -71.8M | 2,280% |
Gain YTD | -10.332 | -6.699 | 154% |
P/E Ratio | N/A | N/A | - |
Revenue | 212M | 87.2M | 243% |
Total Cash | 149M | 862M | 17% |
Total Debt | 103M | 2.55M | 4,034% |
ACB | CRON | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 90 | |
PRICE GROWTH RATING 1..100 | 62 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 1 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRON's Valuation (74) in the Pharmaceuticals Other industry is in the same range as ACB (96). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.
CRON's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACB (100). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.
CRON's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as ACB (91). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.
CRON's Price Growth Rating (60) in the Pharmaceuticals Other industry is in the same range as ACB (62). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.
CRON's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for ACB (100). This means that CRON’s stock grew significantly faster than ACB’s over the last 12 months.
ACB | CRON | |
---|---|---|
RSI ODDS (%) | 3 days ago81% | 3 days ago73% |
Stochastic ODDS (%) | 3 days ago78% | 3 days ago84% |
Momentum ODDS (%) | 3 days ago90% | 3 days ago87% |
MACD ODDS (%) | 3 days ago79% | 3 days ago80% |
TrendWeek ODDS (%) | 3 days ago90% | 3 days ago77% |
TrendMonth ODDS (%) | 3 days ago78% | 3 days ago83% |
Advances ODDS (%) | 14 days ago76% | 17 days ago74% |
Declines ODDS (%) | 4 days ago90% | 4 days ago85% |
BollingerBands ODDS (%) | 3 days ago89% | 3 days ago74% |
Aroon ODDS (%) | 3 days ago90% | 3 days ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
VKSIX | 20.60 | 0.14 | +0.68% |
Virtus KAR Small-Mid Cap Core I | |||
HSMBX | 36.63 | 0.19 | +0.52% |
Horizon Multi-Factor Small/Mid Cap Adv | |||
PBSRX | 14.89 | 0.05 | +0.34% |
Polen US Small Company Growth Investor | |||
BLDRX | 9.39 | 0.03 | +0.32% |
BlackRock Managed Income K | |||
TIBGX | 25.28 | 0.05 | +0.20% |
Thornburg Investment Income Builder R4 |
A.I.dvisor indicates that over the last year, CRON has been closely correlated with TLRY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then TLRY could also see price increases.
Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
---|---|---|---|---|
CRON | 100% | +4.28% | ||
TLRY - CRON | 73% Closely correlated | +8.62% | ||
SNDL - CRON | 73% Closely correlated | +4.05% | ||
ACB - CRON | 67% Closely correlated | +4.15% | ||
CGC - CRON | 67% Closely correlated | +4.43% | ||
OGI - CRON | 64% Loosely correlated | +6.85% | ||
More |